Combination therapy may be an alternative therapeutic approach for difficult-to-treat Candida infections with the aim of increasing efficacy of antifungal therapy. Whether isavuconazole, an extended-spectrum triazole, possesses synergistic activity in combination therapy with echinocandins or polyenes for the treatment of invasive candidiasis has not been studied. We used Bliss independence drug interaction analysis and timekill assays to examine the in vitro interactions of isavuconazole with amphotericin B or micafungin, an echinocandin, against strains of Candida albicans, Candida parapsilosis, Candida glabrata, Candida tropicalis, and Candida krusei. The Bliss independence-based drug interactions modeling showed that the combination of isavuconazole and micafungin resulted in synergistic interactions against C. albicans, C. parapsilosis, and C. krusei. The degree of synergy ranged from 1.8% to 16.7% (mean % E value) with the highest synergy occurring against C. albicans ( SYN% = 8.8%-110%). Time-kill assays showed that the isavuconazole-micafungin combination demonstrated concentrationdepended synergy against C. albicans and C. parapsilosis. The combined interaction by Bliss analysis between isavuconazole and amphotericin B was indifferent for C. albicans, C. parapsilosis, and C. tropicalis while for C. glabrata was antagonistic (−2% to −6%) and C. krusei synergistic (3.4% to 7%). The combination of isavuconazole-amphotericin B by time-kill assay was antagonistic against C. krusei and C. glabrata. Collectively, our 
Introduction
Invasive Candida infections represent a substantial burden to the healthcare system. Combination therapy is increasingly considered as an alternative therapeutic approach for difficult-to-treat Candida infections with the hope of increasing efficacy of antifungal therapy. 1 The availability of several systemic antifungal agents with distinct mechanisms of action against Candida spp. increases the therapeutic potential for combination therapy. Isavuconazole is a new, broad-spectrum triazole with a favorable safety profile and activity against a wide variety of fungal pathogens, including fluconazole-resistant Candida species. 2 With its unique structure-activity relationship, isavuconazole has the potential to enhance antifungal activity, prevent emergence of resistance, and achieve synergy in combination with other agents. 3, 4 The clinical importance as well as the correlation between in vitro combination studies and clinical outcome for Candida is not yet determined. Whether isavuconazole possesses activity in combination with polyenes or echinocandins, is not known. We used Bliss independence drug interaction analysis and time-kill assays to examine the in vitro interactions of isavuconazole with amphotericin B or micafungin, an echinocandin, against strains of Candida albicans, Candida parapsilosis, Candida glabrata, Candida tropicalis, and Candida krusei.
Methods

Organisms
Three to four strains from each of the clinical isolates of C. albicans, C. parapsilosis, C. glabrata, C. tropicalis, and C. krusei were used in experiments. Isolates were obtained from the specimen archives of the TransplantationOncology Infectious Disease Program at Weill Cornell Medical Center of Cornell University. Candida parapsilosis ATCC 22019, a CLSI-validated quality control (QC) strain, was used as an internal control. 5 
Antifungal agents
Amphotericin B deoxycholate (AMB; Sigma-Aldrich, St. Louis, MO, USA) (range, 0.06 to 4.0 μg/ml), micafungin (MFG, Astellas Pharma Inc., Tokyo, Japan) (range, 0.06 to 4.0 μg/ml), and isavuconazole (ISA; Basilea Pharmaceutica, Basel, Switzerland) (range, 0.015 to 1.0 μg/ml) were used in this study for determination of minimum inhibitory concentrations (MICs). These concentrations reflect safely achievable serum levels that are attained by standard dosing. The antifungal agents were obtained in lyophilized powder form and were prepared and preserved according to the manufacturer's instructions. Ninety-six-well plates were prepared using CLSI M27-A3 methodology. The plates contained antifungal agents alone and in checkerboard dilutions of two-drug combinations using concentration ranges slightly modified from those recommended by CLSI document M27-A3. 5 Single drugs or drug combinations were dispensed, into individual wells in 100 μl final volumes. RPMI 1640 medium (Sigma-Aldrich Co., St. Louis, MO, USA) buffered to pH 7.0 with 0.165 M 3-Nmorpholinopropanesulfonic acid (MOPS) (Sigma-Aldrich Co., St. Louis, MO, USA) was used for all drug dilutions. The plates were stored at −70 • C until used.
Minimum inhibitory concentrations
Inocula were prepared from 18-to 24-h-old cultures at 35
• C on Sabouraud glucose agar plates. Each inoculum was adjusted to a 0.5 McFarland standard using a spectrophotometer at a 530-nm wavelength. Twenty milliliters of an inoculum was added to 11 ml of RPMI broth, and after mixing well, 100 μl was dispensed into microtiter wells, to give a final volume of 200 μl (100 μl of antifungal agents and 100 μl of inoculum). The mixture of drugs and inocula was incubated at 35
• C and was read after 24 h and 48 h. The MIC endpoints for yeasts in this study for a single drug correspond to either complete (100% for AMB) or prominent (50% for ISA and MFG) decrease in turbidity (growth inhibition) compared to turbidity in the growth control well. 5 All microplates were performed in triplicate (i.e., three microplates were prepared for each experiment).
In vitro combination testing
The in vitro interactions between ISA and AMB or MFG were studied using a two-dimensional (8 × 12) checkerboard microdilution method in sterile 96-well flat-bottom microtitration plates. ISA and AMB or MFG were added in plate wells as it has been described elsewhere. [6] [7] [8] The antifungal agents were prepared in serial twofold dilution and ranged from 0.008-0.5 μg/ml, 0.03-2, or 0.06-4 μg/ml for MFG, 0.03-2 or 0.06-4 μg/ml for AMB, and 0.002-1, 0.015-8, or 0.06-32 μg/ml for ISA, depending on the susceptibility of the tested isolates. These concentrations were selected to explore the potential for detecting synergy and the lowering of MICs in combination therapy in vitro. Aliquots of 50 μl of each agent at a concentration four times the desired final concentration were applied in the wells of the 96-well culture plates. The plates were stored at −80 • C and defrosted on the day of the experiment. On the experiment day, 100 μl of inoculum was added to each well and plates were incubated for 48 h at 37
• C. After incubation for 48 h, the plates were agitated with gentle vortexing and optical densities with the automated reader plate (Magellan CE PR3100 TSC; Bio-Rad Laboratories, Redmond, WA) at 530 nm were measured. These data were then used to assess percent growth by the following formula: percent growth (optical density [OD] of a well minus the background OD of that well)/(OD of the drug-free well minus the background OD of the drug-free well) × 100%. These data were then used in the Bliss Surface Analysis.
Drug interaction modeling
Interactions between antifungal agents were analyzed using the Bliss independence model. 9 According to Bliss independence model, the expected theoretical percentage of growth (E ind ) (compared to an antifungal agent-free control) describing the effect of the combination of two antifungal agents was calculated with the following equation: E ind = E A × E B where E A and E B are the experimental percentages of growth when each antifungal agent acts alone. For each combination of x μg/ml of antifungal agent A with y μg/ml of antifungal agent B in each of the independent replicate experiments, the experimental observed percentage of growth, E obs , was subtracted from E ind . When the E ( E = E ind -E obs ) was positive and its 95% confidence interval (CI) did not include 0, significant synergy was claimed for the specific combination of xμg/ml of antifungal agent A with yμg/ml of antifungal agent B. When the E was negative without its 95% CI overlapping 0, statistically significant antagonism was claimed. In any other case, indifference was concluded. [10] [11] [12] In order to summarize the whole interaction surface in a value, we calculated the sum percentages of all statistically significant synergistic ( SYN) or antagonistic ( ANT) interactions for our three different combinations. Interactions with <100% were considered weak, those with 100-200% moderate, and those with >200% were considered strong. 6, 12 Time-kill assay
The time-concentration profile of the antifungal activities of ISA alone and in combination with MFG or AMB against C. albicans, C. parapsilosis, C. glabrata, and C. krusei were assessed by the time-killed methodology, as described previously. 125 μg/ml) or AMB (0.5 and 1.0 μg/ml) for C. krusei were studied. Synergism was defined as a decrease in cfu/ml of ≥2 log 10 ; indifference as a difference in cfu/ml of <2 log 10 compared with the most active drug; and antagonism as an increase in cfu/ml ≥2 log 10 compared with the most active drug.
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Results
All Candida isolates grew well after 2 days incubation at 37
• C. In each experiment of broth microdilution tests, the MICs for the quality control strains were within the reference ranges. The range of MICs for the isolates used were for C. albicans 0.1-4 μg/ml (ISA), 0.125-0.25 μg/ml (MFG), and 0.125-0.5 μg/ml (AMB), for C. parapsilosis 0.03-0.125 μg/ml (ISA), 0.125-2 μg/ml (MFG), and 0.25-1 μg/ml (AMB), for C. glabrata 0.125->4 μg/ml (ISA), 0.015-0.125 μg/ml (MFG), and 0.5-4 μg/ml (AMB), for C. tropicalis 4->4 μg/ml (ISA), 0.0625-0.5 μg/ml (MFG), and 0.25-1 μg/ml (AMB), for C. krusei, 0.25-1 μg/ml (ISA), 0.125-1 μg/ml (MFG), and 1 μg/ml (AMB).
ISA-MFG combinations
The results of Bliss independence drug interaction analysis for the in vitro interactions of ISA and MFG are summarized in Table 1 . The combination of ISA-MFG was indifferent for C. glabrata and C. tropicalis and synergistic for C. albicans, C. parapsilosis, and C. krusei. The highest level of synergistic interaction was observed in C. albicans isolates 
Mean (%), the mean % E, where E the difference between the experimental observed percentage of growth subtracted from the calculated according to the Bliss independence model theory (see text). a C ISA and C MFG ; the concentrations of isavuconazole and micafungin, respectively, where the corresponding interaction was observed. b No significant Bliss interaction was found.
SYN% ANT% (n), the sum percentages of all the synergistic or antagonistic interactions, respectively; n, the number of separate combinations with statistically significant synergistic or antagonistic interactions.
(mean % E 16.7% ranging from 12.3% to 20.3% and SYN = 66.9%).
The ISA-MFG combination also had concentration and time-dependent fungicidal activities against C. albicans and C. parapsilosis, as demonstrated by time-kill curves. The combination of ISA 1.0 μg/ml and MFG 0.0625 μg/ml was synergistic at and beyond 8 h against C. albicans; whereas, with higher concentrations of ISA and MFG were indifferent (Fig. 1a) . The rate of killing of C. albicans appeared to be slower at higher concentrations of MFG as the combination of ISA 1.0 μg/ml and MFG 0.125 μg/ml was synergistic at 24 h against C. albicans (Fig. 1b) . Higher concentrations of ISA with MFG 0.125 μg/ml were indifferent against C. albicans. For C. parapsilosis, the combinations of ISA 0.03-1.0 μg/ml and MFG 1.0 μg/ml were synergistic at and beyond 8 h (Fig. 2) , whereas with higher concentrations of ISA and MFG 0.125 μg/ml were indifferent. The combination of ISA-MFG demonstrated indifference against C. glabrata and C. krusei as shown by the time-kill assay. No antagonism was observed for any species evaluated.
ISA-AMB combinations
The results of Bliss independence drug interaction analysis for the in vitro ISA-AMB interactions are summarized in Table 2 . Treatment of C. albicans with ISA (0.06-32 μg/ml) and AMB (0.03-2 μg/ml) in the combined interaction by Bliss analysis between ISA and AMB was indifferent for C. albicans, C. parapsilosis, and C. tropicalis.
The ISA-AMB combination also showed weak antagonistic interaction against C. glabrata over a range of concentrations shown in Table 2 . The ISA-AMB combination showed low-level synergistic interaction only for C. krusei (% E mean 6.2% ranging from 3.4% to 7.2%). Figure 1 . Time-kill assay of isavuconazole and micafungin against C. albicans. The effects of treatment with concentrations of isavuconazole at 1.0 and micafungin at 0.0625 μg/ml (A) and 0.125 μg/ml (B) alone and in combination were studied in relation to no treatment (growth control). Data are plotted as the means ± SE from three separate experiments for each growth curve. As the SE was small for several time points, the error bars may not always be apparent in the time-kill curves. MFG, micafungin; ISA, isavuconazole.
For C. glabrata and C. krusei, time-kill assays demonstrated antagonism in the combination of ISA at 4.0 μg/ml and AMB at 0.5 μg/ml beyond 8 h (Fig. 3a,b) . The combination of ISA-AMB showed indifferent interaction against C. albicans and C. tropicalis in the time-kill assay. Furthermore, the combinations of ISA 0.03-0.5 μg/ml and AMB 0.25 μg/ml were synergistic at and beyond 8 h only against C. parapsilosis, whereas the relatively high concentration Data are plotted as the means ± SE from three separate experiments for each growth curve. As the SE was small for several time points, the error bars may not always be apparent in the time-kill curves. MFG, micafungin; ISA, isavuconazole.
of ISA 1.0 μg/ml combined with AMB 0.25 μg/ml was indifferent (Fig. 4) . Table 3 shows the different patterns of interactions of antifungal agents according to the method used (checkerboard with Bliss independence model analysis and time-kill assays). The ISA-MFG combination was consistently synergistic for C. albicans and C. parapsilosis and indifferent for C. glabrata and C. tropicalis. For C. krusei the interaction patterns differed according to the methods used. Notably, the synergy found by Bliss analysis in C. krusei also was of low level ( SYN = 8.8%, Table 1 ). The ISA-AMB combination was consistently indifferent for C. albicans, and C. tropicalis and consistently antagonistic for C. glabrata (Table 2 ). For C. parapsilosis and C. krusei the drug interaction patterns differed by the method used. The synergistic interaction found in C. krusei by Bliss analysis was of moderate level ( SYN = 111.5%).
Patterns of antifungal drug interaction with isavuconazole
Discussion
Several combinations of antifungal agents are possible: triazole-echinocandin, triazole-polyene, and polyeneechinocandin. Each combination carries important 
Mean (%), the mean % E, where E the difference between the experimental observed percentage of growth subtracted from the calculated according to the Bliss independence model theory (see text). a C ISA and C AMB ; the concentrations of isavuconazole and amphotericin B, respectively, where the corresponding interaction was observed. b No significant Bliss interaction was found.
SYN%/ ANT% (n), the sum percentages of all the synergistic or antagonistic interactions, respectively; n, the number of separate combinations with statistically significant synergistic or antagonistic interactions. Figure 3 . Time-kill assay of isavuconazole and deoxycholate amphotericin B (AMB) against C. glabrata (A) and C. krusei (B). The effects of treatment with concentrations of isavuconazole at 4.0 μg/ml and AMB at 0.5 μg/ml alone and in combination were studied in relation to no treatment (growth control). Data are plotted as the means ± SE from three separate experiments for each growth curve. As the SE was small for several time points, the error bars may not always be apparent in the time-kill curves. MFG, micafungin; AMB, deoxycholate amphotericin B.
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therapeutic implications. Triazole-echinocandin combinations may be especially helpful for isolates that may have elevated MICs to antifungal triazoles. Organisms such as C. glabrata and C. krusei may display elevated MICs (C. glabrata) or be completely resistant (C. krusei and C. glabrata) to triazoles, such as fluconazole or voriconazole.
Conversely, isolates of C. albicans, C. parapsilosis and C. glabrata may have elevated MICs to echinocandins. Elevated MICs or complete resistance may correlate with poor clinical outcome in these settings. 15 In this study, we evaluated the combined effects of isavuconazole (ISA) with an echinocandin (micafungin, MFG) or a polyene (deoxycholate amphotericin B, AMB) against a panel of medically important Candida spp. To our knowledge, this is the first study to examine the combined effects of ISA with other antifungal agents against yeasts. The ISA-MFG combination was consistently synergistic against C. albicans and C. parapsilosis. The ISA-AMB combination was consistently indifferent for C. albicans and C. tropicalis, and antagonistic against C. glabrata. The range of in vitro ISA concentrations, at which the synergistic interactions were observed, fell within safely achievable plasma concentrations of healthy volunteers. 3 ISA is a novel broad-spectrum triazole that was developed to overcome some of the inherent limitations of itraconazole, voriconazole and fluconazole. 16 Among ISA's advantages over the existing antifungal agents are the availability of both intravenous and oral formulation, the absence of a cyclodextrin excipient, the broad spectrum of activity, the linear pharmacokinetic profile and the long half-life. 2 However, many aspects of ISA pharmacokinetics, toxicity, as well as its in vitro activity profile, are not known and warrant further investigation. The triazole-echinocandin interactions were based on the hypothesis that these two classes of antifungal agents may synergistically enhance antifungal activity, as they act at different sites in fungi. Echinocandins, which inhibit cell wall synthesis by disrupting (1→3)-ß-D-glucan synthesis, may enhance the activity of triazoles by increasing the rate or degree of their access to the cell membrane. 15, 17 This study demonstrated that the ISA-MFG .0, and amphotericin B at 0.25 μg/ml alone and in combination were studied in relation to no treatment (growth control). Data are plotted as the means ± SE from three separate experiments for each growth curve. As the SE was small for several time points, the error bars may not always be apparent in the time-kill curves. MFG, micafungin; AMB, deoxycholate amphotericin B.
combination was synergistic for C. albicans, C. parapsilosis and C. krusei. Our findings are compatible with the indifferent-tosynergistic activity previously demonstrated in in vitro and in vivo studies for other combinations to other members of the classes of triazoles and echinocandins against Candida spp.
18,19 Roling et al. using time-kill methods against Candida spp. showed that the combinations of fluconazole-plus-caspofungin or anidulafungin were indifferent. 19 Similarly, further in vitro data demonstrated that the MICs of micafungin-plus-fluconazole were lower than those observed when the agents were tested alone; however, indifference was observed in most cases. Synergistic interactions occurred against 33%, 26%, and 7% of isolates of C. albicans, C. tropicalis and C. glabrata, respectively. 20 Nishi et al. reported that voriconazole-plus-micafungin displayed synergistic activity against C. glabrata, 21 while in a multi-laboratory study this combination was indifferent, possibly due to the different strains tested. 22 Posaconazole and caspofungin also exhibited synergistic antifungal activity without evidence of antagonism against C. glabrata and C. albicans. 23, 24 Collectively, the in vitro studies evaluating the echinocandins in combination with triazoles against Candida spp. show that the interactions are species-specific, while the lack of antagonism and the percentages of synergism against C. albicans warrant further study.
The in vivo implications of the triazole-echinocandin combination was investigated by Graybill et al. in a murine model of candidiasis, which showed that none of the caspofungin-plus-fluconazole combinations led to any benefit over using these antifungal agents alone. 18 On the contrary, in another murine model of disseminated candidiasis, posaconazole in vivo exhibited synergistic antifungal activity with caspofungin. However, this combination therapy was efficacious only against the wild-type C. albicans strain used but not to fluconazole-or to echinocandin-resistant strains, underlying the importance of sufficient dosing in case of drug resistance. 24 These in vitro and in vivo findings
show that triazole-echinocandin combinations have potentially beneficial activity and no apparent deleterious effects, as noted in the in vivo studies, supporting further investigation in terms of further, optimally designed in vivo trials and subsequent clinical trials.
The triazole-polyene interactions may be understood conceptually as either the azole antagonizing the effect of AMB or AMB antagonizing the effect of the azole. 25 Among the proposed mechanisms of triazoles antagonizing AMB is that azoles block the synthesis of ergosterol in the fungal cell membrane resulting in the reduction of AMB binding, since AMB exerts its activity by binding to ergosterol in the cell membrane. 26, 27 An alternative mechanism for the ISA-AMB antagonistic interaction is that absorption to the cell surface by the azole inhibits competitively the binding of AMB to its target site of activity. 26, 28, 29 For AMB's antagonistic effect on the triazole, these hypotheses include the interference by AMB with a cell membrane-associated permease that is likely involved in azole entry into the cell and reduced azole influx due to AMB membrane damage. 30, 31 Despite these theoretical concerns regarding antagonism between these antifungal agents, the high rates of polyene toxicities and the development of azole resistance prompted us to investigate these potentially useful combinations.
Our findings that the ISA-AMB combination is antagonistic against C. glabrata are in concordance with the bulk of previously published in vitro studies that report antagonism between another triazole, fluconazole and amphotericin B after their simultaneous exposure against Candida cells. In a recent multilaboratory study employing the checkerboard assay and the fractional inhibitory index, a synergistic interaction was found for amphotericin B and posaconazole combination against C. glabrata. 22 These results can be attributed to differences in structure-activity relationships among the triazoles, fungal strains, drug concentrations, and experimental designs and analysis. 40 The antagonistic interaction of fluconazole-plusamphotericin B was observed in vivo in one rabbit model of C. albicans endocarditis and pyelonephritis and one murine model of systemic candidiasis. 41, 42 Louie et al. demonstrated that the degree of antagonism between fluconazole and amphotericin B depends on the dose of fluconazole used relative to the fluconazole MIC of the fungal isolate. 42 Sanati et al., using two distinct animal models (a neutropenic mouse model of hematogenously disseminated candidiasis and a rabbit model of infective endocarditis), showed that when fluconazole was given in combination with amphotericin B, combination therapy did not augment the antifungal activity of amphotericin B. Although no significant antagonism was noted, the authors recognize that the number of animals used may not be adequate to statistically exclude antagonism. 43 Furthermore, Sugar et al. in a series of in vivo studies in murine invasive candidiasis model showed that the combination of amphotericin B with fluconazole or other triazoles such as itraconazole, saperconazole, or SCH39304 was not antagonistic, regardless of the immune status of the animals. 29, [44] [45] [46] However, these studies were not optimally designed to identify an antagonistic interaction, given that the 100% survival associated with amphotericin B monotherapy limited the ability to identify antagonism between fluconazole an amphotericin B.
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The correlation between in vitro combination studies and clinical outcomes is not yet determined for isavuconazole. While the number of clinical trials evaluating the interactions between different antifungal agents is very limited, in the landmark randomized clinical trial of Rex et al., evaluating the fluconazole-plus-amphotericin B combination as therapy in nonneutropenic patients with candidemia, it was shown that the in vitro antagonism seen in combination therapy might not always be present in the clinical setting. 47 In conclusion, the in vitro findings of the present study demonstrate that combinations of isavuconazole and micafungin are almost always synergistic against Candida spp., while those of isavuconazole and amphotericin B are mostly indifferent in vitro. The potential in vivo correlation and clinical relevance of these in vitro results warrants further study.
